Simultaneously, KAT8, a gene responsible for the acetylation and degradation of FASN [16], and ZEB1, a transcription factor which is a well-known adipogenesis repressor [17, 18], were upregulated in group II and in the combined groups with cDDGS (II + III + IV) when compared to group I. Recently, it has been proposed that FASN inhibitors have therapeutic utility in diseases associated with elevated lipogenesis, such as obesity, type 2 diabetes, and NAFLD. The gene discussed is ZEB1; the disease is metabolic dysfunction-associated steatotic liver disease.